Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients

J Neuroimmunol. 2016 Nov 15:300:36-46. doi: 10.1016/j.jneuroim.2016.09.013. Epub 2016 Sep 29.

Abstract

We have recently reported the submolecular T-cell recognition profile of the C-terminal half (HC, residues 855-1296) of the heavy (H) chain of botulinum neurotoxin type A (BoNT/A) with peripheral blood lymphocytes (PBL) from 25 BoNT-treated cervical dystonia (CD) patients. In the current study, we describe the mapping of the T-cell responses of the patients to the N-terminal half (HN, residues 449-859) of the heavy chain by using 29 synthetic overlapping peptides encompassing the entire HN domain of BoNT/A. The profiles of the T-cell responses to the peptides varied among the patients. Samples from 14 patients treated solely with BoNT/A recognized 1-9 (average 3.7) peptides/sample at Z>3.0 level. Three peptide regions representing residues 631-649, 659-677 and 743-761 were frequently recognized by 29-64% of the patients. In patients with positive anti-BoNT/A antibody responses the overall positive T cell responses to the HN peptides were significantly increased compared to antibody-negative patients. Influence of treatment parameters on the T-cell recognition of the HN peptides was also observed. The results were compared with those of previously identified HC region.

Keywords: Botulinum neurotoxin type A; Cervical dystonia; H(N) domain; MHC control; Synthetic peptides; T-cell epitopes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amino Acid Sequence
  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use*
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments / genetics
  • Peptide Fragments / immunology*
  • Protein Domains / drug effects
  • Protein Domains / genetics
  • Protein Domains / immunology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • Torticollis / drug therapy*
  • Torticollis / genetics
  • Torticollis / immunology*
  • Treatment Outcome

Substances

  • Peptide Fragments
  • Botulinum Toxins, Type A